| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Studies |
-Subunit of Glycoprotein Hormones
Departments of Medicine (F.N., W.D.H., S.L.), Nuclear Medicine (D.K., E.K.), and Clinical Laboratory (C.S., J.L.), University Hospital Dijkzigt, Rotterdam, The Netherlands; and the Laboratory of Experimental Medicine and Endocrinology, University Hospital Gasthuisberg (W.C., R.B.), Leuven, Belgium
Address all correspondence and requests for reprints to: Dr. F. Nobels, Department of Endocrinology, Onze Lieve Vrouw Hospital, 164 Moorselbaan, 9300 Aalst, Belgium.
Chromogranin A (CgA) is gaining acceptance as a serum marker of
neuroendocrine tumors. Its specificity in differentiating between
neuroendocrine and nonneuroendocrine tumors, its sensitivity to detect
small tumors, and its clinical value, compared with other
neuroendocrine markers, have not clearly been defined, however. The
objectives of this study were to evaluate the clinical usefulness of
CgA as neuroendocrine serum marker. Serum levels of CgA,
neuron-specific enolase (NSE), and the
-subunit of glycoprotein
hormones (
-SU) were determined in 211 patients with neuroendocrine
tumors and 180 control subjects with nonendocrine tumors. The
concentrations of CgA, NSE, and
-SU were elevated in 50%, 43%, and
24% of patients with neuroendocrine tumors, respectively. Serum CgA
was most frequently increased in subjects with gastrinomas (100%),
pheochromocytomas (89%), carcinoid tumors (80%), nonfunctioning
tumors of the endocrine pancreas (69%), and medullary thyroid
carcinomas (50%). The highest levels were observed in subjects with
carcinoid tumors. NSE was most frequently elevated in patients with
small cell lung carcinoma (74%), and
-SU was most frequently
elevated in patients with carcinoid tumors (39%). Most subjects with
elevated
-SU levels also had elevated CgA concentrations. A
significant positive relationship was demonstrated between the tumor
load and serum CgA levels (P < 0.01, by
2 test). Elevated concentrations of CgA, NSE, and
-SU
were present in, respectively, 7%, 35%, and 15% of control subjects.
Markedly elevated serum levels of CgA, exceeding 300 µg/L, were
observed in only 2% of control patients (n = 3) compared to 40%
of patients with neuroendocrine tumors (n = 76). We conclude that
CgA is the best general neuroendocrine serum marker available. It has
the highest specificity for the detection of neuroendocrine tumors
compared to the other neuroendocrine markers, NSE and
-SU. Elevated
levels are strongly correlated with tumor volume; therefore, small
tumors may go undetected. Although its specificity cannot compete with
that of the specific hormonal secretion products of most neuroendocrine
tumors, it can have useful clinical applications in subjects with
neuroendocrine tumors for whom either no marker is available or the
marker is inconvenient for routine clinical use.
This article has been cited by other articles:
![]() |
M. S. Zemskova, E. S. Nylen, N. J. Patronas, E. H. Oldfield, K. L. Becker, and L. K. Nieman Diagnostic Accuracy of Chromogranin A and Calcitonin Precursors Measurements for the Discrimination of Ectopic ACTH Secretion from Cushing's Disease J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2962 - 2965. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. N. Pinchot, K. Holen, R. S. Sippel, and H. Chen Carcinoid Tumors Oncologist, December 1, 2008; 13(12): 1255 - 1269. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Bech, V. Winstanley, K. G. Murphy, A. H. Sam, K. Meeran, M. A. Ghatei, and S. R. Bloom Elevated Cocaine- and Amphetamine-Regulated Transcript Immunoreactivity in the Circulation of Patients with Neuroendocrine Malignancy J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1246 - 1253. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Zatelli, M. Torta, A. Leon, M. R. Ambrosio, M. Gion, P. Tomassetti, F. De Braud, G. Delle Fave, L. Dogliotti, E. C d. Uberti, et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study Endocr. Relat. Cancer, June 1, 2007; 14(2): 473 - 482. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Campana, F. Nori, L. Piscitelli, A. M. Morselli-Labate, R. Pezzilli, R. Corinaldesi, and P. Tomassetti Chromogranin A: Is It a Useful Marker of Neuroendocrine Tumors? J. Clin. Oncol., May 20, 2007; 25(15): 1967 - 1973. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. d'Herbomez, G. Forzy, C. Bauters, C. Tierny, P. Pigny, B. Carnaille, F. Pattou, J.-L. Wemeau, and N. Rouaix An analysis of the biochemical diagnosis of 66 pheochromocytomas Eur. J. Endocrinol., May 1, 2007; 156(5): 569 - 575. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Borglum, J. F. Rehfeld, L. B. Drivsholm, and L. Hilsted Processing-Independent Quantitation of Chromogranin A in Plasma from Patients with Neuroendocrine Tumors and Small-Cell Lung Carcinomas Clin. Chem., March 1, 2007; 53(3): 438 - 446. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Nasr, A. Mason, M. Mayberg, S. M. Staugaitis, and S. L. Asa Acromegaly and Somatotroph Hyperplasia with Adenomatous Transformation Due to Pituitary Metastasis of a Growth Hormone-Releasing Hormone-Secreting Pulmonary Endocrine Carcinoma J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4776 - 4780. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Pals, M. Boussemaere, E. Swinnen, H. Vankelecom, and C. Denef A Pituitary Cell Type Coexpressing Messenger Ribonucleic Acid of Proopiomelanocortin and the Glycoprotein Hormone {alpha}-Subunit in Neonatal Rat and Chicken: Rapid Decline with Age and Reappearance in Vitro under Regulatory Pressure of Corticotropin-Releasing Hormone in the Rat Endocrinology, October 1, 2006; 147(10): 4738 - 4752. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Zuetenhorst and B. G. Taal Metastatic Carcinoid Tumors: A Clinical Review Oncologist, February 1, 2005; 10(2): 123 - 131. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Kaltsas, G. M. Besser, and A. B. Grossman The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors Endocr. Rev., June 1, 2004; 25(3): 458 - 511. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E.M. De Block, G. Colpin, K. Thielemans, W. Coopmans, J. J.P.M. Bogers, P. A. Pelckmans, E. A.E. Van Marck, V. Van Hoof, M. Martin, I. H. De Leeuw, et al. Neuroendocrine Tumor Markers and Enterochromaffin-Like Cell Hyper/Dysplasia in Type 1 Diabetes Diabetes Care, June 1, 2004; 27(6): 1387 - 1393. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Cimitan, A. Buonadonna, R. Cannizzaro, V. Canzonieri, E. Borsatti, R. Ruffo, and L. De Apollonia Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role Ann. Onc., July 1, 2003; 14(7): 1135 - 1141. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Colombo, R. Longhi, C. Marinzi, F. Magni, A. Cattaneo, S. H. Yoo, F. Curnis, and A. Corti Cleavage of Chromogranin A N-terminal Domain by Plasmin Provides a New Mechanism for Regulating Cell Adhesion J. Biol. Chem., November 22, 2002; 277(48): 45911 - 45919. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sugita, M. Geraci, B. Gao, R. L. Powell, F. R. Hirsch, G. Johnson, R. Lapadat, E. Gabrielson, R. Bremnes, P. A. Bunn, et al. Combined Use of Oligonucleotide and Tissue Microarrays Identifies Cancer/Testis Antigens as Biomarkers in Lung Carcinoma Cancer Res., July 15, 2002; 62(14): 3971 - 3979. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Granberg, M. Stridsberg, R. Seensalu, B. Eriksson, G. Lundqvist, K. Öberg, and B. Skogseid Plasma Chromogranin A in Patients with Multiple Endocrine Neoplasia Type 1 J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2712 - 2717. [Abstract] [Full Text] |
||||
![]() |
T. Borglum Jensen, L. Hilsted, and J. F. Rehfeld Library of Sequence-specific Radioimmunoassays for Human Chromogranin A Clin. Chem., April 1, 1999; 45(4): 549 - 560. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Baudin, J.-M. Bidart, P. Rougier, V. Lazar, P. Ruffié, J. Ropers, M. Ducreux, F. Troalen, J.-C. Sabourin, E. Comoy, et al. Screening for Multiple Endocrine Neoplasia Type 1 and Hormonal Production in Apparently Sporadic Neuroendocrine Tumors J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 69 - 75. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |